A share price of Biogen Inc [BIIB] is currently trading at $150.38, up 2.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The BIIB shares have gain 7.03% over the last week, with a monthly amount glided 3.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on February 11, 2025, when Bernstein initiated its Mkt Perform rating and assigned the stock a price target of $160. Previously, Piper Sandler downgraded its rating to Neutral on January 02, 2025, and dropped its price target to $138. On December 20, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $164 on the stock. Stifel downgraded its rating to a Hold but stick to its price target of $175 on December 16, 2024. Jefferies downgraded its rating to Hold for this stock on December 09, 2024, and downed its price target to $180. In a note dated November 18, 2024, Needham downgraded an Hold rating on this stock.
Biogen Inc experienced fluctuations in its stock price throughout the past year between $128.51 and $238.00. Currently, Wall Street analysts expect the stock to reach $233.92 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $150.38 at the most recent close of the market. An investor can expect a potential return of 55.55% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Trailing Twelve Months sales for Biogen Inc [NASDAQ:BIIB] were 9.27B which represents 1.66% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 146.58 points at the first support level, and at 142.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 154.24, and for the 2nd resistance point, it is at 158.09.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biogen Inc [NASDAQ:BIIB] is 1.35. On the other hand, the Quick Ratio is 0.90, and the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 2.38, the price to book ratio is 1.31 and price to earnings (TTM) ratio is 13.45.
Transactions by insiders
Recent insider trading involved STEPHEN A SHERWIN, Director, that happened on Mar 07 ’25 when 8760.0 shares were purchased. Head of Development, Singhal Priya completed a deal on Dec 09 ’24 to sell 110.0 shares. Meanwhile, Officer Singhal Priya bought 110.0 shares on Dec 09 ’24.
